Can a tiny eye implant tame chronic uveitis Flare-Ups?

NCT ID NCT07423442

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 100 adults with non-infectious posterior uveitis, a chronic inflammatory eye disease, who have received a fluocinolone acetonide implant. Researchers will analyze medical records over three years to see how well the implant reduces the frequency and severity of inflammatory relapses and the need for additional treatments. The goal is to better understand the implant's real-world effectiveness and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

fluocinolone acetonide implant (a corticosteroid implant placed in the eye)

What this could lead to

If successful, this study could provide real-world evidence that the fluocinolone implant effectively reduces the number and severity of inflammatory flare-ups in people with chronic uveitis, helping to preserve vision.

What could go wrong

This is an observational study, not a controlled trial, so results may be influenced by other treatments or patient differences. The implant is already approved, so this study is about refining its use, not discovering a new cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEITIC MACULAR EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

posterior uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Nantes - Ophthalmology Department

    Nantes, Nantes, 44000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••